A comprehensive view of Krystal Biotech Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Krystal Biotech receives FDA's fast track designation for inhaled KB707 to treat patients with solid tumors with pulmonary metastases resistant to standard care; the Phase 1 clinical study is expected to begin in 2024
Published: February 14, 2024 by Global Data Point

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count